[go: up one dir, main page]

TNSN98182A1 - Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
TNSN98182A1
TNSN98182A1 TNTNSN98182A TNSN98182A TNSN98182A1 TN SN98182 A1 TNSN98182 A1 TN SN98182A1 TN TNSN98182 A TNTNSN98182 A TN TNSN98182A TN SN98182 A TNSN98182 A TN SN98182A TN SN98182 A1 TNSN98182 A1 TN SN98182A1
Authority
TN
Tunisia
Prior art keywords
preparation
compositions containing
pharmaceutical compositions
novel prostaglandin
prostaglandin agonists
Prior art date
Application number
TNTNSN98182A
Other languages
English (en)
Inventor
Louis Rosati Robert
O'keefe Cameron Kimberly
Allen Lefker Bruce
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN98182A1 publication Critical patent/TNSN98182A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyrrole Compounds (AREA)

Abstract

L’INVENTION CONCERNE DES AGONISTES DE PROSTAGLANDINES DE FORMULE 1 DANS LAQUELLE A, B, G, K, M, Q ET Z REPRESENTENT DIVERS RADICAUX. ELLE CONCERNE EGALEMENT DES COMPOSITIONS LES CONTENANT, ET UN PROCEDE POUR LEUR PREPARATION. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS DANS LE TRAITEMENT DE DIVERSES MALADIES
TNTNSN98182A 1997-10-10 1998-10-09 Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant TNSN98182A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6172797P 1997-10-10 1997-10-10

Publications (1)

Publication Number Publication Date
TNSN98182A1 true TNSN98182A1 (fr) 2005-03-15

Family

ID=22037728

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN98182A TNSN98182A1 (fr) 1997-10-10 1998-10-09 Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (44)

Country Link
US (2) US6498172B1 (fr)
EP (1) EP1021410B1 (fr)
JP (3) JP3664651B2 (fr)
KR (1) KR100369697B1 (fr)
CN (2) CN1566096A (fr)
AP (1) AP1156A (fr)
AR (1) AR015954A1 (fr)
AT (1) ATE349428T1 (fr)
AU (1) AU731509B2 (fr)
BG (1) BG65238B1 (fr)
BR (1) BR9813028A (fr)
CA (1) CA2305548C (fr)
DE (1) DE69836752T2 (fr)
DK (1) DK1021410T3 (fr)
DZ (1) DZ2621A1 (fr)
EA (1) EA003396B1 (fr)
ES (1) ES2277390T3 (fr)
GT (2) GT199800158A (fr)
HN (1) HN1998000157A (fr)
HR (1) HRP20000201B1 (fr)
HU (1) HUP0100101A3 (fr)
ID (1) ID24836A (fr)
IL (2) IL134851A0 (fr)
IS (1) IS5405A (fr)
MA (1) MA26551A1 (fr)
MY (1) MY129189A (fr)
NO (1) NO316733B1 (fr)
NZ (1) NZ503165A (fr)
OA (1) OA11346A (fr)
PA (1) PA8461301A1 (fr)
PE (1) PE121199A1 (fr)
PL (1) PL340014A1 (fr)
PT (1) PT1021410E (fr)
RS (1) RS50012B (fr)
SA (2) SA98190804B1 (fr)
SI (1) SI1021410T1 (fr)
SK (1) SK286136B6 (fr)
TN (1) TNSN98182A1 (fr)
TR (1) TR200000927T2 (fr)
TW (1) TW570913B (fr)
UA (1) UA67754C2 (fr)
UY (1) UY25204A1 (fr)
WO (1) WO1999019300A1 (fr)
ZA (1) ZA989230B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP1000619A3 (fr) * 1998-06-23 2002-07-24 Pfizer Products Inc. Méthode de traitement du glaucome
DE60015508T2 (de) 1999-03-05 2005-04-21 Univ Durham C-16 ungesätigte fp-selektive prostaglandin analoge
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
IL141120A0 (en) 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
WO2003043576A2 (fr) * 2001-11-20 2003-05-30 Depuy Products, Inc. Compositions osteogeniques et chondrogeniques fluentes
HUP0402135A3 (en) * 2001-11-30 2008-04-28 Pfizer Controlled release implant forming polymeric compositions of bone growth promoting compounds and process for their preparation
BR0214614A (pt) * 2001-11-30 2004-09-14 Pfizer Prod Inc Composições farmacêuticas e métodos para a administração de agonistas seletivos de receptor ep2
JP2005521668A (ja) * 2002-01-31 2005-07-21 ファイザー・プロダクツ・インク （３−｛［４−ｔｅｒｔ−ブチル−ベンジル）−（ピリジン−３−スルホニル）−アミノ］−メチル｝−フェノキシ）−酢酸の代謝物
WO2003087061A1 (fr) 2002-04-12 2003-10-23 Pfizer Japan Inc. Composes de pyrazole en tant qu'agents anti-inflammatoires et analgesiques
BR0311263A (pt) 2002-05-24 2005-04-26 Pharmacia Corp Moduladores anilino receptores-x do fìgado
CA2486651A1 (fr) 2002-05-24 2003-12-04 Pharmacia Corporation Modulateurs de recepteur x hepatique a base de sulfone
JP2006021998A (ja) * 2002-07-18 2006-01-26 Ono Pharmaceut Co Ltd Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
EP1563846B1 (fr) 2002-10-10 2012-08-29 Ono Pharmaceutical Co., Ltd. Promoteurs de production de facteurs de reparation endogenes
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
EP1601351A1 (fr) * 2003-03-04 2005-12-07 Pfizer Products Inc. Utilisation d'agonistes selectifs du recepteur ep2 dans un traitement medical
US20070270489A1 (en) 2003-07-25 2007-11-22 Ono Pharmaceutical Co., Ltd. Remedy for Cartilage-Related Diseases
WO2005027931A1 (fr) * 2003-09-19 2005-03-31 Pfizer Products Inc. Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un agoniste selectif de ep2 ou ep4
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
WO2005123191A1 (fr) * 2004-06-21 2005-12-29 Pharmacia & Upjohn Company Llc Inhibiteurs de pyk2 pour la stimulation de la fonction de l'osteoblaste
WO2006028970A1 (fr) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derives d'inhibiteurs de thiazole et de thiadiazole de tyrosine phosphatases
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
WO2006073973A2 (fr) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Nouveaux dérivés de benzylamine en tant qu'inhibiteurs de cetp
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
EP2494990A1 (fr) 2005-06-03 2012-09-05 Ono Pharmaceutical Co., Ltd. Agent pour la régénération et/ou la protection des nerfs
US7915316B2 (en) 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
UA94953C2 (en) * 2006-07-28 2011-06-25 Пфайзер Продактс Инк. Ep2 agonists
EA200970067A1 (ru) 2006-07-28 2009-08-28 Пфайзер Продактс Инк. Агонисты ep2
US8183286B2 (en) 2006-11-16 2012-05-22 Gemmus Pharma Inc. EP2 and EP4 agonists as agents for the treatment of influenza a viral infection
US9394520B2 (en) * 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
NZ583350A (en) * 2007-08-21 2012-03-30 Senomyx Inc Heteroaryl-hydantoin derivatives as bitter taste inhibitors
WO2009027803A2 (fr) * 2007-08-29 2009-03-05 Pfizer Products Inc. Formes polymorphes d'acide libre d'acide acétique 3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-méthyl)- phénoxy)
AU2008291814A1 (en) * 2007-08-29 2009-03-05 Pfizer Products Inc. Polymorphs of 3- ( ( (4-tert-butyl-benzyl) - (pyridine-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid sodium salt or a hydrate thereof and methods for making the same
US20110046385A1 (en) * 2007-08-29 2011-02-24 Pfizer Products Inc. Polymorphs Of Prostaglandin Agonists And Methods For Making The Same
HUE042839T2 (hu) * 2008-03-12 2019-07-29 Ube Industries Piridilaminoecetsav vegyületek
EP2149551A1 (fr) 2008-07-30 2010-02-03 Bayer Schering Pharma AG Dérivés de N-(indol-3-ylalkyl)-(hétéro)arylamide en tant que modulateurs du récepteur EP2
EP2149552A1 (fr) 2008-07-30 2010-02-03 Bayer Schering Pharma AG Dérivés de benzamide 5,6 substitués en tant que modulateurs du récepteur EP2
EP2149554A1 (fr) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamides en tant que modulateurs du récepteur EP2
JP5300033B2 (ja) 2009-03-30 2013-09-25 宇部興産株式会社 緑内障の治療又は予防のための医薬組成物
WO2010116270A1 (fr) 2009-04-10 2010-10-14 Pfizer Inc. Agonistes de ep2/4
WO2011078303A1 (fr) 2009-12-25 2011-06-30 宇部興産株式会社 Composé d'aminopyridine
KR101362639B1 (ko) 2010-09-16 2014-02-13 연세대학교 산학협력단 중간엽 줄기세포의 연골 세포로의 분화 유도를 위한 화합물의 용도
MX2014001849A (es) 2011-08-18 2014-10-24 Reddys Lab Ltd Dr Compuestos de amina heterociclicos sustituidos como inhibidores de proteina de transferencia de ester colesterilo (cetp).
EP2760864B1 (fr) 2011-09-27 2018-01-24 Dr. Reddy's Laboratories Ltd. DÉRIVÉS DE 5-BENZYLAMINOMÉTHYL-6-AMINOPYRAZOLO[3,4-b]PYRIDINE COMME INHIBITEURS DE LA CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) UTILES POUR LE TRAITEMENT DE L'ATHÉROSCLÉROSE
US8772541B2 (en) * 2011-12-15 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
JP6400479B2 (ja) 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
CN105143187B (zh) 2013-02-28 2018-04-03 武田药品工业株式会社 制备磺酰氯化合物的方法
EP2980075A4 (fr) 2013-03-28 2016-08-10 Ube Industries Composé biaryle substitué
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
JP2017206444A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換フェニル化合物
CN114591227A (zh) * 2021-12-28 2022-06-07 上海冬洋生物科技有限公司 一种ep2受体选择性的前列腺素e2激动剂的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR897566A (fr) 1942-08-28 1945-03-26 Bopp & Reuther Gmbh Machine à rotors
US3442890A (en) 1965-06-15 1969-05-06 Mead Johnson & Co Substituted 3-benzazocin-16-ones
US3528961A (en) 1966-08-16 1970-09-15 Allied Chem Monoazo dyes from e-caprolactam
US3780095A (en) 1970-04-08 1973-12-18 Byk Gulden Lomberg Chem Fab Acylated anilino-carboxylic acids and their salts
US3987091A (en) 1973-04-12 1976-10-19 Merck & Co., Inc. 11,12-secoprostaglandins
US4033996A (en) 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
JPS5019756A (fr) 1973-06-25 1975-03-01
SE7414770L (fr) 1973-12-13 1975-06-16 Merck & Co Inc
DK366475A (da) 1974-08-30 1976-03-01 Merck & Co Inc Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US3991106A (en) 1974-09-13 1976-11-09 Merck & Co., Inc. 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4055596A (en) * 1974-09-13 1977-10-25 Merck & Co., Inc. 11,12-Seco-prostaglandins
US4175203A (en) 1976-12-17 1979-11-20 Merck & Co., Inc. Interphenylene 11,12-secoprostaglandins
US4112236A (en) 1977-04-04 1978-09-05 Merck & Co., Inc. Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
US4097601A (en) * 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4243678A (en) 1977-12-30 1981-01-06 Byk Gulden Lomberg Chemische Fabrik Gmbh Acylhydrocarbylaminoalkanoic acids, compositions and uses
DE3000377A1 (de) 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3042482A1 (de) 1980-11-11 1982-06-24 A. Nattermann & Cie GmbH, 5000 Köln N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA1214170A (fr) 1981-06-16 1986-11-18 Patrick Choay Procedes de preparation de nouveaux composes du type arylbenzenesulfonamide
FI832935A7 (fi) 1982-08-20 1984-02-21 Midit Derivat av w-aminosyror, deras framstaellning samt dessa derivat innehaollande blandningar
DE3719046A1 (de) 1987-06-06 1988-12-15 Basf Ag Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5081152A (en) 1989-07-05 1992-01-14 Kotobuki Seiyaku Co., Ltd. Azulene derivatives as thromboxane a2 and prostaglandin endoperoxide receptor antagonist
JPH0467105A (ja) * 1990-07-09 1992-03-03 Nippon Telegr & Teleph Corp <Ntt> 偏波保持光ファイバ
GB9110722D0 (en) * 1991-05-17 1991-07-10 Fujisawa Pharmaceutical Co Amine derivatives
GB9116732D0 (en) * 1991-08-02 1991-09-18 Fujisawa Pharmaceutical Co Indole derivatives
CA2113787A1 (fr) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Sulfonamides carbocycliques
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
DE19648793A1 (de) * 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
AUPO440696A0 (en) * 1996-12-30 1997-01-23 Fujisawa Pharmaceutical Co., Ltd. New use
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
BR0214614A (pt) * 2001-11-30 2004-09-14 Pfizer Prod Inc Composições farmacêuticas e métodos para a administração de agonistas seletivos de receptor ep2
JP2005521668A (ja) * 2002-01-31 2005-07-21 ファイザー・プロダクツ・インク （３−｛［４−ｔｅｒｔ−ブチル−ベンジル）−（ピリジン−３−スルホニル）−アミノ］−メチル｝−フェノキシ）−酢酸の代謝物

Also Published As

Publication number Publication date
DE69836752D1 (de) 2007-02-08
US6498172B1 (en) 2002-12-24
UA67754C2 (uk) 2004-07-15
CN1211367C (zh) 2005-07-20
IS5405A (is) 2000-03-14
DZ2621A1 (fr) 2003-03-08
AR015954A1 (es) 2001-05-30
BG65238B1 (bg) 2007-09-28
DK1021410T3 (da) 2007-04-02
US7442702B2 (en) 2008-10-28
SK4752000A3 (en) 2001-05-10
GT199800158AA (es) 2000-04-01
HRP20000201A2 (en) 2000-06-30
AU9181598A (en) 1999-05-03
NO20001754D0 (no) 2000-04-05
HRP20000201B1 (en) 2003-06-30
TR200000927T2 (tr) 2000-11-21
NO316733B1 (no) 2004-04-14
JP2007246532A (ja) 2007-09-27
HUP0100101A2 (hu) 2001-06-28
NZ503165A (en) 2001-07-27
SA98190804B1 (ar) 2006-07-30
EP1021410B1 (fr) 2006-12-27
SK286136B6 (sk) 2008-04-07
IL134851A (en) 2007-06-17
EA003396B1 (ru) 2003-04-24
HK1031884A1 (en) 2001-06-29
WO1999019300A1 (fr) 1999-04-22
EP1021410A1 (fr) 2000-07-26
ATE349428T1 (de) 2007-01-15
ID24836A (id) 2000-08-24
SA98190804A (ar) 2005-12-03
JP4796006B2 (ja) 2011-10-19
AP1156A (en) 2003-06-30
NO20001754L (no) 2000-06-07
SI1021410T1 (sl) 2007-06-30
MY129189A (en) 2007-03-30
PT1021410E (pt) 2007-02-28
PE121199A1 (es) 1999-12-02
YU18400A (sh) 2003-08-29
AU731509B2 (en) 2001-03-29
EA200000298A1 (ru) 2000-10-30
JP2001519414A (ja) 2001-10-23
ZA989230B (en) 2000-04-10
TW570913B (en) 2004-01-11
HUP0100101A3 (en) 2001-12-28
HN1998000157A (es) 1999-06-02
OA11346A (en) 2003-12-11
CA2305548C (fr) 2008-12-02
BG104315A (en) 2000-12-29
CA2305548A1 (fr) 1999-04-22
JP3664651B2 (ja) 2005-06-29
JP4031736B2 (ja) 2008-01-09
MA26551A1 (fr) 2004-12-20
CN1275123A (zh) 2000-11-29
KR100369697B1 (ko) 2003-02-05
US20030078261A1 (en) 2003-04-24
IL134851A0 (en) 2001-05-20
RS50012B (sr) 2008-09-29
AP9801356A0 (en) 1998-12-31
PL340014A1 (en) 2001-01-15
CN1566096A (zh) 2005-01-19
KR20010031035A (ko) 2001-04-16
JP2004155759A (ja) 2004-06-03
DE69836752T2 (de) 2007-10-11
PA8461301A1 (es) 2000-05-24
BR9813028A (pt) 2000-08-15
SA06260449B1 (ar) 2007-08-07
ES2277390T3 (es) 2007-07-01
GT199800158A (es) 2000-04-01
UY25204A1 (es) 2000-12-29

Similar Documents

Publication Publication Date Title
TNSN98182A1 (fr) Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99053A1 (fr) Hydroxamides d&#39;acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN99055A1 (fr) Derives bicycliques d&#39;acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN02014A1 (fr) Composes nouveaux agonistes de ppar et compositions les contenant
TNSN99106A1 (fr) Derives d&#39;isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98019A1 (fr) Derives d&#39;acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97122A1 (fr) Inhibiteurs des metalloproteinases de matrice a base de phosphinates
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97144A1 (fr) Derives 6,6-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98022A1 (fr) DERIVES DE N-HYDROXY-β-SULFONYLPROPIONAMIDE, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT.
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN02015A1 (fr) Composes nouveaux antagonistes de ppar, et compositions les contenant
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99253A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00121A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN98238A1 (fr) Macrolides nouveaux
TNSN99162A1 (fr) Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99156A1 (fr) Derives d&#39;acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.